1:44 PM
 | 
Feb 14, 2018
 |  BC Extra  |  Company News

Viaskin Peanut data sufficient for BLA

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Wednesday that FDA has agreed that the available safety and efficacy data for peanut allergy candidate Viaskin Peanut (DBV-712) will support a BLA submission for the product. DBV plans to submit the...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >